Please use this identifier to cite or link to this item:
Title: T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques
Authors: CHAMPIAT, StephaneGARRISON, Keith E.RAPOSO, Rui Andre SaraivaBURWITZ, Benjamin J.REED, JasonTANDON, RaviYORK, Vanessa A.NEWMAN, Laura P.NIMITYONGSKUL, Francesca A.WILSON, Nancy A.ALMEIDA, Rafael R.MARTIN, Jeffrey N.DEEKS, Steven G.ROSENBERG, Michael G.WIZNIA, Andrew A.SPOTTS, Gerald E.PILCHER, Christopher D.HECHT, Fredrick M.OSTROWSKI, Mario A.SACHA, Jonah B.NIXON, Douglas F.
Citation: JOURNAL OF VIROLOGY, v.87, n.11, p.6073-6080, 2013
Abstract: APOBEC3 proteins mediate potent antiretroviral activity by hypermutating the retroviral genome during reverse transcription. To counteract APOBEC3 and gain a replicative advantage, lentiviruses such as human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) have evolved the Vif protein, which targets APOBEC3 proteins for proteasomal degradation. However, the proteasome plays a critical role in the generation of T cell peptide epitopes. Whether Vif-mediated destruction of APOBEC3 proteins leads to the generation and presentation of APOBEC3-derived T cell epitopes on the surfaces of lentivirus-infected cells remains unknown. Here, using peptides derived from multiple Vif-sensitive APOBEC3 proteins, we identified APOBEC3-specific T cell responses in both HIV-1-infected patients and SIV-infected rhesus macaques. These results raise the possibility that these T cell responses may be part of the larger antiretroviral immune response.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - LIM/60
LIM/60 - Laboratório de Imunologia Clínica e Alergia

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.4 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.